Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faden, A. I.
Right arrow Articles by Brown, C. Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faden, A. I.
Right arrow Articles by Brown, C. Q.
NEUROLOGY 1982;32:1083
© 1982 American Academy of Neurology

Treatment of experimental stroke

Comparison of naloxone and thyrotropin releasing hormone

Alan I. Faden, M.D., John M. Hallenbeck, M.D. and Carlton Q. Brown, M.D.

Hyperbaric Medicine Program Center (Drs. Faden, Hallenbeck, and Brown) Naval Medical Research Institute, and The Neurobiology Research Unit (Dr. Faden), Uniformed Services University of the Health Sciences, Bethesda, MD.

The effects of naloxone and thyrotropin releasing hormone (TRH) were compared in an incremental air embolization model of experimental stroke in dogs. Naloxone treatment significantly improved the cortical somatosensory evoked response and had a beneficial effect on local cerebral blood flow, whereas TRH treatment had no effect on these variables. These findings may implicate endorphins in the pathophysiology of stroke and indicate that naloxone may have a therapeutic role in this condition. Moreover, the lack of effect of TRH in this model, in contrast to its therapeutic effect in experimental spinal injury, indicates that the pathophysiologic responses to ischemic cerebral injury and traumatic spinal injury may differ.

Address correspondence and reprint requests to Dr. Faden. Chief, Neurobiology Research Unit, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.

Accepted for publication March 30, 1982.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
V. Soonthon-Brant, P. M. Patel, J. C. Drummond, D. J. Cole, P. J. Kelly, and M. Watson
Fentanyl Does Not Increase Brain Injury After Focal Cerebral Ischemia in Rats
Anesth. Analg., January 1, 1999; 88(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. W. Yum and A. I. Faden
Comparison of the Neuroprotective Effects of the N-Methyl-D-Aspartate Antagonist MK-801 and the Opiate-Receptor Antagonist Nalmefene in Experimental Spinal Cord Ischemia
Arch Neurol, March 1, 1990; 47(3): 277 - 281.
[Abstract] [PDF]

Home page
 J Intensive Care MedHome page
L. R. Wechsler
Analytic Reviews : Potential New Therapies for Acute Ischemic Stroke
J Intensive Care Med, September 1, 1988; 3(5): 258 - 264.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
A. I. Faden
Neuropeptides and Central Nervous System Injury: Clinical Implications
Arch Neurol, May 1, 1986; 43(5): 501 - 504.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by AAN Enterprises, Inc.